News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
The addition of pembrolizumab to neoadjuvant chemotherapy in the phase III KEYNOTE-756 – European Society for Medical Oncology
Jan 29, 2025, 18:07

The addition of pembrolizumab to neoadjuvant chemotherapy in the phase III KEYNOTE-756 – European Society for Medical Oncology

ESMO – European Society for Medical Oncology shared a post on LinkedIn:

“The addition of pembrolizumab to neoadjuvant chemotherapy in the phase III KEYNOTE-756 significantly improves the pathological complete response rate in patients with high-risk, early-stage ER+/HER2− Breast Cancer.

Read the full news on ESMO Daily Reporter.”

pembrolizumab

 

Breast Cancer cancer ESMO ESMO Daily Reporter European Society for Medical Oncology fight against cancer Global fight against cancer HER2 KEYNOTE-756 neoadjuvant chemotherapy OncoDaily Oncology pembrolizumab
Special Coverage
Science
Apr 2, 2025, 11:04
Shilpa Gupta: Safety and tolerability of maintenance avelumab in elderly patients subgroup from Javelin Bladder 100 trial
Science
Apr 2, 2025, 10:53
Diego A. Díaz García: Cross-priming is key in cancer immunotherapy
Science
Apr 2, 2025, 10:29
Bishal Gyawali: Congruence of cancer screening recommendations between the USPSTF and the top ten US cancer centers
Blog
Apr 2, 2025, 10:15
IMF Regional Community Workshop to learn all about MM - International Myeloma Foundation
Blog
Apr 2, 2025, 10:10
Ready to coordinate Advisory Board in Basilicata to improve oncology research - Sbarro Health Research Organization
Blog
Apr 2, 2025, 10:07
Teresa Amaral: Discussing neoadjuvant therapy in skin cancer at the 27th International Dermatology Meeting
Blog
Apr 2, 2025, 10:05
Wafaa M Rashed: Personalized HIV Treatment in Africa
Career
Apr 2, 2025, 10:01
Karen Knudsen: I’ve taken the helm of Parker Institute for Cancer Immunotherapy (PICI) as CEO
Blog
Apr 2, 2025, 09:58
John F. Kurland presented about immuno-oncology therapies at the IO360 Summit
Blog
Apr 2, 2025, 09:54
ACC 2025 Clinical Trials to Watch with Deepak Bhatt - Mount Sinai Department of Medicine
Blog
Apr 2, 2025, 09:46
Orouba Almilaji: NATCAN - improving the quality of National Health Service cancer care in England and Wales
Blog
Apr 2, 2025, 09:45
Susanna Fletcher Greer: The V Foundation grantee Stefani Thomas and her team explored PDX models in ovarian cancer